



US010377824B2

(12) **United States Patent**
Lonberg et al.

(10) **Patent No.:** **US 10,377,824 B2**
(45) **Date of Patent:** **Aug. 13, 2019**

(54) **OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF**

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**, Princeton, NJ (US)

(72) Inventors: **Nils Lonberg**, Woodside, CA (US);
Mohan Srinivasan, Cupertino, CA (US)

(73) Assignee: **Bristol-Myers Squibb Company**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/125,028**

(22) Filed: **Sep. 7, 2018**

(65) **Prior Publication Data**

US 2018/0371087 A1 Dec. 27, 2018

Related U.S. Application Data

(60) Division of application No. 15/296,290, filed on Oct. 18, 2016, which is a division of application No. 14/093,867, filed on Dec. 2, 2013, now Pat. No. 9,505,839, which is a continuation of application No. PCT/US2013/048999, filed on Jul. 2, 2013.

(60) Provisional application No. 61/667,058, filed on Jul. 2, 2012.

(51) **Int. Cl.**

A61K 38/36 (2006.01)

A61K 39/395 (2006.01)

C07K 16/28 (2006.01)

A61K 45/06 (2006.01)

A61K 47/68 (2017.01)

C07K 16/30 (2006.01)

A61K 39/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/2803** (2013.01); **A61K 45/06** (2013.01); **A61K 47/6849** (2017.08); **C07K 16/28** (2013.01); **C07K 16/2818** (2013.01); **C07K 16/2827** (2013.01); **A61K 39/39558** (2013.01); **A61K 2039/507** (2013.01); **C07K 16/3061** (2013.01); **C07K 2317/14** (2013.01); **C07K 2317/21** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/75** (2013.01); **C07K 2317/76** (2013.01); **C07K 2317/92** (2013.01); **C07K 2317/94** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,773,578 A 6/1998 Hercend et al.
5,874,250 A 2/1999 Hercend et al.

5,976,877 A 11/1999 Hercend et al.
6,143,273 A 11/2000 Faure et al.
6,197,524 B1 3/2001 Romagnani
6,482,925 B1 11/2002 El Tayar et al.
RE38,313 E 11/2003 Faure et al.
7,138,501 B2 11/2006 Ruben et al.
7,306,906 B2 12/2007 Maruyama et al.
7,329,737 B2 2/2008 Sexton et al.
7,563,441 B2 7/2009 Graus et al.
7,595,048 B2 9/2009 Honjo et al.
7,605,238 B2 10/2009 Korman et al.
7,790,160 B2 9/2010 Von Strandmann et al.
7,850,965 B2 12/2010 Jensen et al.
7,943,743 B2 5/2011 Korman et al.
8,008,449 B2 8/2011 Korman et al.
8,168,179 B2 5/2012 Honjo et al.
8,383,796 B2 2/2013 Korman et al.
8,728,474 B2 5/2014 Honjo et al.
(Continued)

FOREIGN PATENT DOCUMENTS

JP 2006340714 A 12/2006
WO WO-9110682 A1 7/1991

(Continued)

OTHER PUBLICATIONS

Agrawal, S., et al., "Clinical Pharmacokinetics (PK) of BMS-936558, a Fully Human Anti-pd-1 Monoclonal Antibody," Journal of Clinical Oncology 30(15):1 (2012), ASCO Annual Meeting Website, [retrieved on Jan. 13, 2015]. Retrieved from the Internet : URL: <http://www.meetinglibrary.asco.org/content/98623-114>.

(Continued)

Primary Examiner — Michail A Belyavskyi

(74) *Attorney, Agent, or Firm* — Sterne, Kessler, Goldstein & Fox P.L.L.C.

(57) **ABSTRACT**

The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.

30 Claims, 15 Drawing Sheets

Specification includes a Sequence Listing.